Table of Contents Table of Contents
Previous Page  26 / 34 Next Page
Information
Show Menu
Previous Page 26 / 34 Next Page
Page Background

The dilemma of choosing the 2nd line

treatment in RCC: Points to consider

1. Grande E,

et al

.

World J Clin Oncol

2017;8(2):100–5; 2. Eggers H,

et al

.

J Kidney Cancer VHL

2017;4:8–15.; 3. Signorovitch J,

et al

.

Curr Med Res Op

2014;30:2343–53.

Sunitinib/

pazopanib

?

Tolerability to 1st line treatment

1

Time of clinical benefit to 1st line

1

Tumour growth rate after progression to 1st line

1

Symptoms/burden of disease

1

Sites of metastasis

1

MSKCC/Heng’s prognosis

2

Age/comorbidities/ECOG PS

2,3